ӳ��ý

Cancer Program

The power of parent scientists.

Boehm JS. The power of parent scientists. Cell. 2021;184(9):2263-2270. doi:10.1016/j.cell.2021.03.049

Predicting cell health phenotypes using image-based morphology profiling.

Way GP, Kost-Alimova M, Shibue T, et al. Predicting cell health phenotypes using image-based morphology profiling. Mol Biol Cell. 2021;32(9):995-1005. doi:10.1091/mbc.E20-12-0784

Splice it up: Atypical transcripts to boost leukemia immunotherapy.

Cieri N, Wu CJ. Splice it up: Atypical transcripts to boost leukemia immunotherapy. Immunity. 2021;54(4):608-610. doi:10.1016/j.immuni.2021.03.016

A first-generation pediatric cancer dependency map.

Dharia NV, Kugener G, Guenther LM, et al. A first-generation pediatric cancer dependency map. Nat Genet. 2021;53(4):529-538. doi:10.1038/s41588-021-00819-w

Bridging the gap between cancer cell line models and tumours using gene expression data.

Noorbakhsh J, Vazquez F, McFarland JM. Bridging the gap between cancer cell line models and tumours using gene expression data. Br J Cancer. 2021. doi:10.1038/s41416-021-01359-0

A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective.

Kwon JJ, Hahn WC. A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective. Mol Cell Biol. 2021;41(4). doi:10.1128/MCB.00627-20

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.

Penter L, Zhang Y, Savell A, et al. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021. doi:10.1182/blood.2021010867

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.

Bi K, He MX, Bakouny Z, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021. doi:10.1016/j.ccell.2021.02.015

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.

Braun DA, Street K, Burke KP, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021. doi:10.1016/j.ccell.2021.02.013

In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.

Dubrot J, Lane-Reticker SK, Kessler EA, et al. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity. 2021;54(3):571-585.e6. doi:10.1016/j.immuni.2021.01.001